Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-28

Study Completion Date

2016-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectomy

NCT02992041

Post-Operative Pain

COMPLETED PHASE2

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty

NCT03997838

Pain, Postoperative

COMPLETED PHASE3

Intravenous Lidocaine for Cystectomy Procedures

NCT02924480

Invasive Bladder Cancer

COMPLETED NA

Enhanced Recovery After Laparoscopic Colorectal Surgery

NCT05406765

Rectal Cancer Postoperative Pain

COMPLETED PHASE4

Randomized Study Comparing the Use of Epidural Analgesia to Intravenous Narcotics for Laparoscopic Colorectal Resection.

NCT02086123

Pain, Postoperative

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain transmission by the brain and reduces nociceptor activation in peripheral nerves, which are primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable efficacy to morphine in well controlled (blind, complete randomization with a positive control) animal studies using rat models of post-operative pain and formalin-induced pain. The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure level is more than 2,000 ng/ml.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VVZ-149 Injections

Group Type EXPERIMENTAL

VVZ-149 Injections

Intervention Type DRUG

Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo group will receive the corresponding amount of placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VVZ-149 Injections

Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.

Intervention Type DRUG

Placebo

Placebo group will receive the corresponding amount of placebo.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Opiranserin Injections

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women age between 18-70, inclusive.
2. Pain intensity (NRS) ≥4 at initial post-operative measurement in PACU.
3. Subjects undergoing planned laparoscopic colorectal surgery.
4. Ability to provide written informed consent.
5. Ability to understand study procedures and communicate clearly with the investigator and staff.
6. American Society of Anesthesiologists (ASA) risk class of I to III.

Exclusion Criteria

\< Surgical Factors \>

1. Emergency or unplanned surgery.
2. Repeat operation (e.g., previous surgery within 30 days for same condition).
3. Cancer-related condition causing preoperative pain in site of surgery.

\< Subject Characteristics \>
4. Women with childbearing potential (Women age 18-55 must undergo pregnancy test).
5. Women who are pregnant or breastfeeding.
6. Chronic pain diagnosis (e.g., ongoing pain at baseline with NRS ≥ 4/10).
7. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression) Subjects who take stable doses (same dose \>30 days) of antidepressants and anti-anxiety drugs may be included.
8. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS).

\< Drug, Alcohol, and Pharmacological Considerations \>
9. Renal or hepatic impairment.
10. History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening (TICS alcohol/drug screen will be performed at Screening).
11. Ongoing or recent (within 30 days prior to surgery) use of steroids, opioids, or antipsychotics.
12. Alcohol consumption within 24 hours of surgery.
13. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 24 hours of surgery.
14. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery.

\< Anesthetic and Other Exclusion Considerations \>
15. Use of neuraxial or regional anesthesia related to the surgery.
16. Use of local anesthetic wound infiltration \> 20 ml of 1% lidocaine
17. Use of ketamine, gabapentin, pregabalin, or lidocaine (\>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery.
18. Subjects with known allergies to hydromorphone.
19. Subjects who received another investigational drug within 30 days of scheduled surgery.
20. Subjects who have long PR (\>200 msec) or prolonged QTc (\> 450 msec) at Screening or on an EKG done immediately prior to dosing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No